Active, not recruitingNot applicableNCT01464606
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
Studying DICER1 tumor-predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospitals and Clinics of Minnesota
- Principal Investigator
- Kris Ann P Schultz, MDChildren's Hospitals and Clinics of Minnesota
- Intervention
- Vincristine(drug)
- Enrollment
- 156 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2009 – 2028
Study locations (1)
- Anne K Harris, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01464606 on ClinicalTrials.govOther trials for DICER1 tumor-predisposition syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06647953Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary BlastomaChildren's Oncology Group
- RECRUITINGNCT01247597DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyNational Cancer Institute (NCI)